Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P02671
UPID:
FIBA_HUMAN
Alternative names:
-
Alternative UPACC:
P02671; A8K3E4; D3DP14; D3DP15; Q4QQH7; Q9BX62; Q9UCH2
Background:
The Fibrinogen alpha chain plays a pivotal role in hemostasis, forming an insoluble fibrin matrix crucial for blood clotting. Beyond its primary function, it aids in wound repair, platelet expression, and successful pregnancy. Its involvement extends to infection defense and immune response facilitation.
Therapeutic significance:
Linked to Congenital afibrinogenemia, Amyloidosis 8, and Dysfibrinogenemia, the Fibrinogen alpha chain's genetic variants underscore its clinical importance. Understanding its role could unveil new therapeutic strategies for these conditions.